Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This study evaluates the outcomes and critical factors influencing the success of tisagenlecleucel therapy for children and young adults with B-cell acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplant across Euro
This study compares outcomes after allogeneic stem cell transplantation using post-transplant cyclophosphamide in AML patients achieving first remission with one versus two induction courses, revealing similar survival but higher relapse wi
TP53 mutations define a high-risk AML subset with inferior survival post-allo-HCT, driven mainly by relapse. Molecular heterogeneity may guide personalized post-transplant strategies.
This article reviews the variability and comparative effectiveness of re-induction treatments in pediatric relapsed AML, highlighting the role of gemtuzumab ozogamicin and chemotherapy backbones in improving remission rates but not overall
A study of 2,577 haploidentical transplants shows that extended HLA haplotypes, including a class III SNP, significantly influence mortality and relapse, potentially improving donor selection.
A propensity-weighted analysis suggests that shorter antithyroid drug therapy (<12 months) in Graves' disease patients with low baseline TRAb is broadly comparable to the standard 12-18 months in preventing relapse, supporting indiv
Early immune profiling after allogeneic stem cell transplant was linked to survival and relapse risk. Stronger innate and adaptive immune recovery predicted better outcomes, while certain activation and checkpoint markers were associated wi
A study of 91 B-ALL patients found that relapse after CD19/CD22 dual-target CAR T-cell therapy is mainly driven by CAR T-cell functional failure and antigen loss, with PAX5 mutations linked to early immune escape.
An international expert consensus offers standardized, operational criteria for defining relapse in schizophrenia to reduce study heterogeneity, improve research comparability, and guide clinical reporting.
This study compares long-acting injectable to oral antipsychotics in older schizophrenia patients, highlighting benefits in relapse prevention and mortality reduction, with specific considerations for adverse effects.
A randomized clinical trial reveals early dose reduction of antipsychotics after first-episode psychosis remission increases short-term relapse risk and lowers quality of life, but may improve long-term functioning over four years.